Replication Stress Signatures

$361,839P01FY2017CANIH

University Of Washington, Seattle WA

Investigators

Linked publications & trials

Paper 38619278 Paper 37824763 Paper 36761837 Paper 36549742 Paper 35412430 Paper 35303493 Paper 35045296 Paper 34968384 Paper 34606690 Paper 33857147 Paper 33279516 Paper 33039802 Paper 32648584 Paper 32109764 Paper 31900199 Paper 31748270 Paper 31694907 Paper 31540485 Paper 31269435 Paper 31181796 Paper 31010849 Paper 30625989 Paper 30401823 Paper 30389308 Paper 30291105 Paper 30107528 Paper 30042204 Paper 29766388 Paper 29754406 Paper 29717454 Paper 29617664 Paper 29576615 Paper 29523243 Paper 29298978 Paper 29223992 Paper 29146545 Paper 28809863 Paper 28798064 Paper 28652129 Paper 28276523 Paper 28170390 Paper 27859906 Paper 27672210 Paper 27559010 Paper 27543334 Paper 27197248 Paper 27197159 Paper 27158641 Paper 27130890 Paper 27121793 Paper 26993153 Paper 26987311 Paper 26984941 Paper 26702772 Paper 26355458 Paper 26216839 Paper 26186366 Paper 26150098 Paper 26021206 Paper 25994221 Paper 25849638 Paper 25810110 Paper 25699289 Paper 25663616 Paper 25492499 Paper 25310185 Paper 25299156 Paper 25079325 Paper 24958861 Paper 24928506 Paper 24914050 Paper 24859205 Paper 24809800 Paper 24793120 Paper 24677773 Paper 24609361 Paper 24556991 Paper 24178577 Paper 24086148 Paper 23908689 Paper 23874207 Paper 23794700 Paper 23790955 Paper 23770608 Paper 23733015 Paper 23713831 Paper 23684799 Paper 23671119 Paper 23637633 Paper 23604118 Paper 23592419 Paper 23573208 Paper 23519618 Paper 23396845 Paper 23396353 Paper 23386316 Paper 23283971 Paper 23253856 Paper 23065663 Paper 22973417

Abstract

PROJECT 2 ? Summary Goal: Our goal is to determine how tumor-specific replication abnormalities can be used to develop more effective anti-cancer therapies for adult acute myelogenous leukemia (AML) and glioblastoma multiforme (GBM), two rapidly lethal, treatment-refractory tumors. Our organizing hypothesis is that aberrant replication is common in AML and GBM, and represents an opportunity to improve treated survival by identifying drugs, small molecules and treatment regimens that synergize with replication defects to promote cell killing. Innovations: The Project 2 Research Plan has the following innovative features: ? Replication and replication abnormalities as tumor-specific therapeutic vulnerabilities in AML and GBM, a focus viewed as ?very novel? in prior review. ? DNA replication fork dynamics analyzed at the single molecule level. ? Network modeling to link replication abnormalities to genomic instability and therapeutic response. ? Microfluidic culture of GBM tissue on a novel platform to enable multiplexed drug profiling. ? Mixed-genotype competitive growth assays to determine mutant fitness?and thus potential therapeutic importance?in culture and in xenografts. Approach/Aims: We have three inter-related Aims collectively focused on defining DNA replication behavior and therapeutic response in AML, GSCs and GBM tissue. Aim 1: Define AML replication dynamics and the role of aberrant replication in therapeutic response. Aim 2: Define GBM replication dynamics and the role of aberrant replication in therapeutic response. Aim 3: Identify mutation-dependent mechanisms that drive subclonal heterogeneity and therapeutic resistance (a collaborative Project Aim). Impact: The proposed research will provide or develop: ? Detailed picture of mutation-dependent replication dynamics in AML and GBM. ? Link altered replication dynamics influence therapeutic response in AML and GBM. ? Identify or predict potentially effective new therapies and regimens for AML and GBM. ? Test potential new therapeutic vulnerabilities using clinically relevant preclinical models.

View original record on NIH RePORTER →